NASDAQ:IXHL Incannex Healthcare Q1 2026 Earnings Report $3.44 +0.05 (+1.47%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$3.42 -0.02 (-0.73%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Incannex Healthcare EPS ResultsActual EPS-$0.60Consensus EPS -$11.70Beat/MissBeat by +$11.10One Year Ago EPSN/AIncannex Healthcare Revenue ResultsActual Revenue$0.05 millionExpected Revenue$0.20 millionBeat/MissMissed by -$152.00 thousandYoY Revenue GrowthN/AIncannex Healthcare Announcement DetailsQuarterQ1 2026Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time4:00PM ETUpcoming EarningsIncannex Healthcare's Q4 2026 earnings is estimated for Thursday, September 24, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, September 30, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly Report(10-Q) Incannex Healthcare Earnings HeadlinesIncannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital PositionSeptember 9, 2026 | globenewswire.comIncannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep ApneaAugust 25, 2026 | quiverquant.comQWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing. | The Oxford Club (Ad)Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42XAugust 25, 2026 | globenewswire.comIncannex Healthcare Inc.August 15, 2026 | cnn.comIncannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026August 11, 2026 | finance.yahoo.comSee More Incannex Healthcare Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Incannex Healthcare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Incannex Healthcare and other key companies, straight to your email. Email Address About Incannex HealthcareIncannex Healthcare (NASDAQ:IXHL) Limited (NASDAQ: IXHL) is a clinical-stage biotechnology company developing pharmaceutical products and therapies for conditions with significant unmet medical needs. The company’s research focuses on cannabinoid- and psychedelic-assisted treatments, with programs addressing sleep-disordered breathing, pain, inflammation, mental health and other complex disorders. One of Incannex’s principal programs is IHL-42X, an investigational combination of dronabinol and acetazolamide being developed for obstructive sleep apnea. The company has also pursued cannabinoid-based candidates for inflammatory and fibrotic diseases, pain conditions and traumatic brain injury, as well as psychedelic-assisted therapies for psychiatric disorders such as generalized anxiety disorder. These products remain investigational and are subject to clinical and regulatory review. Founded in Australia, Incannex has conducted research and clinical development activities in Australia and the United States. The company’s securities trade on the Nasdaq Capital Market under the symbol IXHL, and it has historically been led by Managing Director and Chief Executive Officer Joel Latham. Incannex’s development strategy is centered on advancing its drug candidates through clinical trials and, where appropriate, seeking regulatory approval and commercialization partnerships.View Incannex Healthcare ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
